The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
IMS 2024 | Frailty-adapted therapy in myeloma: session takeaways
In this video, Ashley Rosko, MD, Ohio State University Comprehensive Cancer Center, Columbus, OH, outlines some key points from a session on frailty-adapted therapy in multiple myeloma (MM), highlighting its importance in clinical practice and clinical trial settings. This interview took place at the 21st International Myeloma Society (IMS) Annual Meeting, held in Rio de Janeiro, Brazil.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
